<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01290874</url>
  </required_header>
  <id_info>
    <org_study_id>2010p001898</org_study_id>
    <nct_id>NCT01290874</nct_id>
  </id_info>
  <brief_title>Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)</brief_title>
  <acronym>BELT</acronym>
  <official_title>Blacks and Exacerbations on LABA vs. Tiotropium (BELT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Olmsted Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Academy of Family Physicians National Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baim Institute for Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are doing this study to learn how genes affect the way that people, specifically Black
      people, respond to treatment for asthma. Recent studies suggest that people respond
      differently to some asthma medications (eg Serevent, Foradil). Some people feel better when
      they use these inhalers, but others may not, and some people get worse. It seems that this
      difference shows up more often in Blacks than in Whites, which is why we are looking for
      Black subjects for this study. In all people, this difference seems to depend on their genes
      or DNA. This study is comparing the use of long acting asthma medications (Serevent, Foradil)
      to Tiotropium (Spiriva) for the treatment of asthma. Spiriva is used to treat chronic
      obstructive pulmonary disease (COPD). This study will help to see if this medication is also
      useful for treating asthma and whether it works better for some people than the current
      asthma medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asthma is a chronic respiratory disease that affects over 22 million people in the United
      States. Asthma produces 500,000 hospital admissions and accounts for 10.1 million days of
      lost work in adults annually. Asthma has been designated a priority condition of the
      Effective Health Care Program.

      Blacks bear a disproportionate burden of asthma morbidity and mortality. In its 2005 report
      on ethnic disparities in health care, AHRQ identified hospital admissions for asthma as the
      second largest disparity in quality of health care for Blacks vs. Caucasians.

      Long-acting beta-agonists (LABAs) produce extended increases in airway caliber among patients
      with asthma via action at the beta2-adrenergic receptor (ADRB2). Adding a LABA to an inhaled
      corticosteroid controller medication (ICS), can decrease asthma symptoms for many individuals
      and appears to decrease asthma exacerbations. LABA/ICS has become the most commonly
      prescribed ICS containing medication.

      Drugs acting at ADRB2, including LABAs, have been associated with rare loss of long-term
      asthma control and increased serious adverse outcomes including death and respiratory
      failure, even when used with ICS. The risk appears four to five-fold greater in Blacks than
      non-Black patients with asthma.

      Consensus guidelines recommend LABAs be added to ICS in those not completely controlled on
      ICS alone. These recommendations are based on weighing data on the benefit demonstrated in
      the general population vs. the rare risk of serious adverse outcomes and balancing the
      apparent benefits vs. the risks of LABAs (Kramer 2009). However, it appears that LABA/ICS may
      be significantly less effective in Blacks than Caucasians. Comparison of studies with
      LABA/ICS in Blacks vs. studies where Blacks were a small minority suggests that Blacks may
      have much less benefit than other racial groups. Additionally, recent data (Wechsler 2009)
      suggest that a polymorphism at the 16th position of the ADRB2 gene identifies a group of
      Blacks (those homozygous for arginine (Arg16Arg)) in whom the response of adding a LABA to an
      ICS is further diminished. This polymorphism is present in ~20% of US Blacks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 30, 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Asthma Exacerbation (Mean Number of Exacerbations/Person-year)</measure>
    <time_frame>evaluated monthly (on average) via questionnaire for 12 months</time_frame>
    <description>We summarize the survival experience using mean number of exacerbations/person-year and compare it using the log-rank test comparing kaplan-meier survival curve.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1</measure>
    <time_frame>from baseline to 12 months</time_frame>
    <description>Average change in lung function (FEV1) evaluated by spirometry per participant over 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Asthma Control Questionnaire (ACQ)</measure>
    <time_frame>from baseline to 12 months</time_frame>
    <description>Average Change in Asthma Control Score Per Participant Over 12 Months Using the Asthma Control Questionnaire (ACQ).
The ACQ has six questions regarding symptoms, rescue short-acting Î²-agonist use and one about FEV1 % predicted. A 7-point scale (0 = no impairment, 6 = maximum impairment) is used for each question and the ACQ score is the mean value of these questions - hence between 0 (totally controlled) and 6 (severely uncontrolled).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Asthma Quality of Life (AQLQ)</measure>
    <time_frame>from baseline to 12 months</time_frame>
    <description>Average Change in Asthma Quality of Life Score Per Participant Over 12 Months Using the Asthma Quality of Life Questionnaire (AQLQ).
The AQLQ has 32 questions in four domains (symptoms, activity limitation, emotional function, and environmental stimuli) and measures the functional problems that are troublesome to individuals with asthma. Symptoms (11 items), Activity Limitation (12 items, 5 of which are individualized), Emotional Function (5 items), and Environmental Exposure (4 items); 7-point Likert scale (7 = not impaired at all - 1 = severely impaired); scores range 1-7, with higher scores indicating better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Asthma Symptom Utility Index (ASUI)</measure>
    <time_frame>from baseline to 12 months</time_frame>
    <description>Average Change in Asthma Symptom Utility Score Per Participant Over 12 Months Using the Asthma Symptom Utility Index (ASUI).
The ASUI is an 11-item preference-based outcome measure used in clinical trials and cost-effectiveness studies for asthma and is designed to assess the frequency and severity of cough, wheeze, dyspnea, nighttime awakenings, and side effects, weighted according to patient preferences.
4-point Likert scale to assess frequency (not at all, 1 to 3 days, 4 to 7 days, and 8 to 14 days) and severity (not applicable, mild, moderate and severe); scores range from 0 (worst possible symptoms) to 1 (no symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Symptom-Free Day Questionnaire (SFDQ)</measure>
    <time_frame>from baseline to 12 months</time_frame>
    <description>Average Change in Symptom-Free Days Per Participant Over 12 Months Using the Symptom-Free Day Questionnaire (SFDQ).
The asthma symptom free day questionnaire (SFDQ) quantifies the number of days with neither daytime nor nighttime asthma symptoms, nor awakenings due to asthma symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rescue Medication Use</measure>
    <time_frame>from baseline to 12 months</time_frame>
    <description>Average Change in Rescue Medication Use Per Participant Over 12 Months. Monthly questionnaires will evaluate the amount of rescue medication subjects have used on average, measured in puffs per day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Moderate Asthma Deterioration</measure>
    <time_frame>from baseline to 12 months</time_frame>
    <description>Average Change in Moderate Asthma Deterioration Per Participant Over 12 Months. The definition of a moderate asthma deterioration should include one or more of the following: deterioration in symptoms, deterioration in lung function, or increased rescue bronchodilator use. These features should last for 2 days or more, but not be severe enough to warrant systemic corticosteroid use and/or hospitalization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1070</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Tiotropium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tiotropium bromide will be evaluated as a treatment for asthma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salmeterol or Formoterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>Tiotropium bromide 18 mcg once daily for one year of treatment.</description>
    <arm_group_label>Tiotropium</arm_group_label>
    <other_name>Spiriva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol</intervention_name>
    <description>Salmeterol 50 mcg twice daily for one year of treatment.</description>
    <arm_group_label>Salmeterol or Formoterol</arm_group_label>
    <other_name>Serevent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol</intervention_name>
    <description>Formoterol 12 mcg twice daily for one year</description>
    <arm_group_label>Salmeterol or Formoterol</arm_group_label>
    <other_name>Foradil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Black (self-identified, with at least one biological parent identified as Black)

          2. Male and female subjects, ages 18-75

          3. Ability to provide informed consent

          4. Clinical history consistent with asthma for &gt; 1 year.

          5. Ability to perform pulmonary function tests

          6. FEV1 &gt; 40% of predicted

          7. Receiving inhaled corticosteroids (ICS)/LABA combination therapy, or ICS moderate dose
             monotherapy and baseline ACQ&gt;1.25

          8. Non-smoker for past year (total lifetime smoking history &lt; 10 pack-years)

        Exclusion Criteria:

          1. Use of greater than the equivalent of 1000 mcg inhaled fluticasone daily

          2. Chronic use of oral corticosteroids or Anti IgE for asthma

          3. Lung disease other than asthma or diagnosis of vocal cord dysfunction.

          4. Significant medical illness (other than asthma) that is not stable.

          5. Pregnancy or lactation or an unwillingness to maintain effective birth control.

          6. History of a significant exacerbation of asthma or respiratory tract infection in the
             prior 4 weeks

          7. History of life-threatening asthma requiring treatment with intubation and mechanical
             ventilation within 5 years.

          8. Hypo sensitization therapy other than an established maintenance regimen.

          9. Use of inhaled anticholinergic therapy (ipratropium, tiotropium) in prior month

         10. Known contraindication to inhaled tiotropium e.g. narrow angle glaucoma, history of
             bladder neck obstruction or significant symptoms related to prostatic hypertrophy.

         11. Inability to speak and read English.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elliot Israel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Edward Waters College Medical Center (Mayo)</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urban Family Practice</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Area Primary Healthcare, Inc</name>
      <address>
        <city>Newton</city>
        <state>Georgia</state>
        <zip>39870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G.A. Carmichael F.H.C.</name>
      <address>
        <city>Canton</city>
        <state>Mississippi</state>
        <zip>39046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swope Parkway Health Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Group</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNYNET - Jefferson Family Medicine</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center - NorthEast (Lovelace)</name>
      <address>
        <city>Kannapolis</city>
        <state>North Carolina</state>
        <zip>28081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Medicine Occupational Health Center</name>
      <address>
        <city>Shaker Heights</city>
        <state>Ohio</state>
        <zip>44120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BJHCHS - Hardeeville Medical Center</name>
      <address>
        <city>Ridgeland</city>
        <state>South Carolina</state>
        <zip>29936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wechsler ME, Yawn BP, Fuhlbrigge AL, Pace WD, Pencina MJ, Doros G, Kazani S, Raby BA, Lanzillotti J, Madison S, Israel E; BELT Investigators. Anticholinergic vs Long-Acting Î²-Agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma: The BELT Randomized Clinical Trial. JAMA. 2015 Oct 27;314(16):1720-30. doi: 10.1001/jama.2015.13277.</citation>
    <PMID>26505596</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2010</study_first_submitted>
  <study_first_submitted_qc>February 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2011</study_first_posted>
  <results_first_submitted>March 6, 2017</results_first_submitted>
  <results_first_submitted_qc>March 28, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 30, 2018</results_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Elliot Israel, MD</investigator_full_name>
    <investigator_title>Director of the Asthma Research Center</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Blacks</keyword>
  <keyword>LABA</keyword>
  <keyword>Tiotropium</keyword>
  <keyword>Spiriva</keyword>
  <keyword>African American</keyword>
  <keyword>Serevent</keyword>
  <keyword>salmeterol</keyword>
  <keyword>Foradil</keyword>
  <keyword>formoterol</keyword>
  <keyword>Advair</keyword>
  <keyword>Symbicort</keyword>
  <keyword>Dulera</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Initial enrollment began March 30, 2011 at the Asthma Research Center at Brigham and Women's Hospital. Subjects were recruited with print advertisements, internet postings, physician referrals, and by contacting patients in databases who asked to be contacted for studies.</recruitment_details>
      <pre_assignment_details>Subjects on combination ICS/LABA were switched to equivalent-dose ICS monotherapy at the same time they were assigned to the Tiotropium vs. LABA arm of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tiotropium</title>
          <description>Tiotropium: Tiotropium bromide 18 mcg once daily for one year of treatment.</description>
        </group>
        <group group_id="P2">
          <title>Salmeterol or Formoterol</title>
          <description>Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.
Salmeterol: Salmeterol 50 mcg twice daily for one year of treatment.
Formoterol: Formoterol 12 mcg twice daily for one year</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="532"/>
                <participants group_id="P2" count="538"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="410"/>
                <participants group_id="P2" count="404"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tiotropium</title>
          <description>Tiotropium bromide will be evaluated as a treatment for asthma.
Tiotropium: Tiotropium bromide 18 mcg once daily for one year of treatment.</description>
        </group>
        <group group_id="B2">
          <title>Salmeterol or Formoterol</title>
          <description>Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.
Salmeterol: Salmeterol 50 mcg twice daily for one year of treatment.
Formoterol: Formoterol 12 mcg twice daily for one year</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="532"/>
            <count group_id="B2" value="538"/>
            <count group_id="B3" value="1070"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.2" spread="12.6"/>
                    <measurement group_id="B2" value="45.1" spread="12.6"/>
                    <measurement group_id="B3" value="45.15" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="405"/>
                    <measurement group_id="B2" value="408"/>
                    <measurement group_id="B3" value="813"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="501"/>
                    <measurement group_id="B2" value="502"/>
                    <measurement group_id="B3" value="1003"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="532"/>
                    <measurement group_id="B2" value="538"/>
                    <measurement group_id="B3" value="1070"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Asthma Exacerbation (Mean Number of Exacerbations/Person-year)</title>
        <description>We summarize the survival experience using mean number of exacerbations/person-year and compare it using the log-rank test comparing kaplan-meier survival curve.</description>
        <time_frame>evaluated monthly (on average) via questionnaire for 12 months</time_frame>
        <population>intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium: Tiotropium bromide 18 mcg once daily for one year of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol or Formoterol</title>
            <description>Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.
Salmeterol: Salmeterol 50 mcg twice daily for one year of treatment.
Formoterol: Formoterol 12 mcg twice daily for one year</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Asthma Exacerbation (Mean Number of Exacerbations/Person-year)</title>
          <description>We summarize the survival experience using mean number of exacerbations/person-year and compare it using the log-rank test comparing kaplan-meier survival curve.</description>
          <population>intention-to-treat</population>
          <units>event per person-year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="532"/>
                <count group_id="O2" value="538"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" lower_limit="0.32" upper_limit="0.43"/>
                    <measurement group_id="O2" value="0.42" lower_limit="0.36" upper_limit="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FEV1</title>
        <description>Average change in lung function (FEV1) evaluated by spirometry per participant over 12 months</description>
        <time_frame>from baseline to 12 months</time_frame>
        <population>255 and 253 participants are missing data on change in FEV1 in the Tiotropium and Salmeterol or Formoterol arms, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium: Tiotropium bromide 18 mcg once daily for one year of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol or Formoterol</title>
            <description>Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.
Salmeterol: Salmeterol 50 mcg twice daily for one year of treatment.
Formoterol: Formoterol 12 mcg twice daily for one year</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FEV1</title>
          <description>Average change in lung function (FEV1) evaluated by spirometry per participant over 12 months</description>
          <population>255 and 253 participants are missing data on change in FEV1 in the Tiotropium and Salmeterol or Formoterol arms, respectively.</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="285"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.018" lower_limit="-0.047" upper_limit="0.012"/>
                    <measurement group_id="O2" value="0.003" lower_limit="-0.026" upper_limit="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Asthma Control Questionnaire (ACQ)</title>
        <description>Average Change in Asthma Control Score Per Participant Over 12 Months Using the Asthma Control Questionnaire (ACQ).
The ACQ has six questions regarding symptoms, rescue short-acting Î²-agonist use and one about FEV1 % predicted. A 7-point scale (0 = no impairment, 6 = maximum impairment) is used for each question and the ACQ score is the mean value of these questions - hence between 0 (totally controlled) and 6 (severely uncontrolled).</description>
        <time_frame>from baseline to 12 months</time_frame>
        <population>334 and 326 participants are missing data on ACQ in the Tiotropium and Salmeterol or Formoterol arms, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium: Tiotropium bromide 18 mcg once daily for one year of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol or Formoterol</title>
            <description>Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.
Salmeterol: Salmeterol 50 mcg twice daily for one year of treatment.
Formoterol: Formoterol 12 mcg twice daily for one year</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Asthma Control Questionnaire (ACQ)</title>
          <description>Average Change in Asthma Control Score Per Participant Over 12 Months Using the Asthma Control Questionnaire (ACQ).
The ACQ has six questions regarding symptoms, rescue short-acting Î²-agonist use and one about FEV1 % predicted. A 7-point scale (0 = no impairment, 6 = maximum impairment) is used for each question and the ACQ score is the mean value of these questions - hence between 0 (totally controlled) and 6 (severely uncontrolled).</description>
          <population>334 and 326 participants are missing data on ACQ in the Tiotropium and Salmeterol or Formoterol arms, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" lower_limit="-0.81" upper_limit="-0.60"/>
                    <measurement group_id="O2" value="-0.66" lower_limit="-0.77" upper_limit="-0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Asthma Quality of Life (AQLQ)</title>
        <description>Average Change in Asthma Quality of Life Score Per Participant Over 12 Months Using the Asthma Quality of Life Questionnaire (AQLQ).
The AQLQ has 32 questions in four domains (symptoms, activity limitation, emotional function, and environmental stimuli) and measures the functional problems that are troublesome to individuals with asthma. Symptoms (11 items), Activity Limitation (12 items, 5 of which are individualized), Emotional Function (5 items), and Environmental Exposure (4 items); 7-point Likert scale (7 = not impaired at all - 1 = severely impaired); scores range 1-7, with higher scores indicating better quality of life.</description>
        <time_frame>from baseline to 12 months</time_frame>
        <population>242 and 239 participants are missing data on AQLQ in the Tiotropium and Salmeterol or Formoterol arms, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium: Tiotropium bromide 18 mcg once daily for one year of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol or Formoterol</title>
            <description>Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.
Salmeterol: Salmeterol 50 mcg twice daily for one year of treatment.
Formoterol: Formoterol 12 mcg twice daily for one year</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Asthma Quality of Life (AQLQ)</title>
          <description>Average Change in Asthma Quality of Life Score Per Participant Over 12 Months Using the Asthma Quality of Life Questionnaire (AQLQ).
The AQLQ has 32 questions in four domains (symptoms, activity limitation, emotional function, and environmental stimuli) and measures the functional problems that are troublesome to individuals with asthma. Symptoms (11 items), Activity Limitation (12 items, 5 of which are individualized), Emotional Function (5 items), and Environmental Exposure (4 items); 7-point Likert scale (7 = not impaired at all - 1 = severely impaired); scores range 1-7, with higher scores indicating better quality of life.</description>
          <population>242 and 239 participants are missing data on AQLQ in the Tiotropium and Salmeterol or Formoterol arms, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.88" upper_limit="1.12"/>
                    <measurement group_id="O2" value="1.02" lower_limit="0.90" upper_limit="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Asthma Symptom Utility Index (ASUI)</title>
        <description>Average Change in Asthma Symptom Utility Score Per Participant Over 12 Months Using the Asthma Symptom Utility Index (ASUI).
The ASUI is an 11-item preference-based outcome measure used in clinical trials and cost-effectiveness studies for asthma and is designed to assess the frequency and severity of cough, wheeze, dyspnea, nighttime awakenings, and side effects, weighted according to patient preferences.
4-point Likert scale to assess frequency (not at all, 1 to 3 days, 4 to 7 days, and 8 to 14 days) and severity (not applicable, mild, moderate and severe); scores range from 0 (worst possible symptoms) to 1 (no symptoms).</description>
        <time_frame>from baseline to 12 months</time_frame>
        <population>257 and 265 participants are missing data on ASUI in the Tiotropium and Salmeterol or Formoterol arms, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium bromide will be evaluated as a treatment for asthma.
Tiotropium: Tiotropium bromide 18 mcg once daily for one year of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol or Formoterol</title>
            <description>Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.
Salmeterol: Salmeterol 50 mcg twice daily for one year of treatment.
Formoterol: Formoterol 12 mcg twice daily for one year</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Asthma Symptom Utility Index (ASUI)</title>
          <description>Average Change in Asthma Symptom Utility Score Per Participant Over 12 Months Using the Asthma Symptom Utility Index (ASUI).
The ASUI is an 11-item preference-based outcome measure used in clinical trials and cost-effectiveness studies for asthma and is designed to assess the frequency and severity of cough, wheeze, dyspnea, nighttime awakenings, and side effects, weighted according to patient preferences.
4-point Likert scale to assess frequency (not at all, 1 to 3 days, 4 to 7 days, and 8 to 14 days) and severity (not applicable, mild, moderate and severe); scores range from 0 (worst possible symptoms) to 1 (no symptoms).</description>
          <population>257 and 265 participants are missing data on ASUI in the Tiotropium and Salmeterol or Formoterol arms, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="0.09" upper_limit="0.13"/>
                    <measurement group_id="O2" value="0.10" lower_limit="0.08" upper_limit="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Symptom-Free Day Questionnaire (SFDQ)</title>
        <description>Average Change in Symptom-Free Days Per Participant Over 12 Months Using the Symptom-Free Day Questionnaire (SFDQ).
The asthma symptom free day questionnaire (SFDQ) quantifies the number of days with neither daytime nor nighttime asthma symptoms, nor awakenings due to asthma symptoms.</description>
        <time_frame>from baseline to 12 months</time_frame>
        <population>The instrument used to collect data proved to be unreliable. The statistic for internal consistency demonstrated less than 30% internal consistency.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium bromide will be evaluated as a treatment for asthma.
Tiotropium: Tiotropium bromide 18 mcg once daily for one year of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol or Formoterol</title>
            <description>Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.
Salmeterol: Salmeterol 50 mcg twice daily for one year of treatment.
Formoterol: Formoterol 12 mcg twice daily for one year</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Symptom-Free Day Questionnaire (SFDQ)</title>
          <description>Average Change in Symptom-Free Days Per Participant Over 12 Months Using the Symptom-Free Day Questionnaire (SFDQ).
The asthma symptom free day questionnaire (SFDQ) quantifies the number of days with neither daytime nor nighttime asthma symptoms, nor awakenings due to asthma symptoms.</description>
          <population>The instrument used to collect data proved to be unreliable. The statistic for internal consistency demonstrated less than 30% internal consistency.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Rescue Medication Use</title>
        <description>Average Change in Rescue Medication Use Per Participant Over 12 Months. Monthly questionnaires will evaluate the amount of rescue medication subjects have used on average, measured in puffs per day.</description>
        <time_frame>from baseline to 12 months</time_frame>
        <population>335 and 328 participants are missing data on rescue medication use in the Tiotropium and Salmeterol or Formoterol arms, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium: Tiotropium bromide 18 mcg once daily for one year of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol or Formoterol</title>
            <description>Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.
Salmeterol: Salmeterol 50 mcg twice daily for one year of treatment.
Formoterol: Formoterol 12 mcg twice daily for one year</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Rescue Medication Use</title>
          <description>Average Change in Rescue Medication Use Per Participant Over 12 Months. Monthly questionnaires will evaluate the amount of rescue medication subjects have used on average, measured in puffs per day.</description>
          <population>335 and 328 participants are missing data on rescue medication use in the Tiotropium and Salmeterol or Formoterol arms, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" lower_limit="-1.27" upper_limit="-0.57"/>
                    <measurement group_id="O2" value="-0.97" lower_limit="-1.32" upper_limit="-0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Moderate Asthma Deterioration</title>
        <description>Average Change in Moderate Asthma Deterioration Per Participant Over 12 Months. The definition of a moderate asthma deterioration should include one or more of the following: deterioration in symptoms, deterioration in lung function, or increased rescue bronchodilator use. These features should last for 2 days or more, but not be severe enough to warrant systemic corticosteroid use and/or hospitalization.</description>
        <time_frame>from baseline to 12 months</time_frame>
        <population>Inadequate baseline data was collected so that the change in this variable could not be assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium bromide will be evaluated as a treatment for asthma.
Tiotropium: Tiotropium bromide 18 mcg once daily for one year of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol or Formoterol</title>
            <description>Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.
Salmeterol: Salmeterol 50 mcg twice daily for one year of treatment.
Formoterol: Formoterol 12 mcg twice daily for one year</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Moderate Asthma Deterioration</title>
          <description>Average Change in Moderate Asthma Deterioration Per Participant Over 12 Months. The definition of a moderate asthma deterioration should include one or more of the following: deterioration in symptoms, deterioration in lung function, or increased rescue bronchodilator use. These features should last for 2 days or more, but not be severe enough to warrant systemic corticosteroid use and/or hospitalization.</description>
          <population>Inadequate baseline data was collected so that the change in this variable could not be assessed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported from the time of patient enrollment to up to 18 months after study completion.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tiotropium</title>
          <description>Tiotropium: Tiotropium bromide 18 mcg once daily for one year of treatment.</description>
        </group>
        <group group_id="E2">
          <title>Salmeterol or Formoterol</title>
          <description>Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.
Salmeterol: Salmeterol 50 mcg twice daily for one year of treatment.
Formoterol: Formoterol 12 mcg twice daily for one year</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Cardiac Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Coronary Artery Occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Dysponea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Abdominal Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Diverticulum Intestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Hiatus Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Impaired Gastric Emptying</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="532"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Disease Progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladder Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bacterial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Localized Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Mental status change</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="532"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="532"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="338" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="342" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease Progression</sub_title>
                <counts group_id="E1" events="211" subjects_affected="211" subjects_at_risk="532"/>
                <counts group_id="E2" events="203" subjects_affected="203" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="127" subjects_affected="127" subjects_at_risk="532"/>
                <counts group_id="E2" events="139" subjects_affected="139" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Elliot Israel</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>6177328201</phone>
      <email>eisrael@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

